Cancer is an unprecedented proliferation of cells leading to abnormalities in differentiation
and maturation. Treatment of primary and metastatic cancer is challenging. In addition to …

As one of the main threats to human life (the fourth most dangerous and prevalent cancer),
colorectal cancer affects many people yearly, decreases patients' quality of life, and causes …

Immunotherapies comprising programmed cell death protein 1/PD ligand 1 (PD‐1/PD‐L1)
immune checkpoint inhibitors are effective cancer treatments. However, the low response …

Proficient mismatch repair or microsatellite stable (pMMR/MSS) colorectal cancers (CRCs)
are vastly outnumbered by deficient mismatch repair or microsatellite instability-high …

Objectives: The antitumor activity of nivolumab plus regorafenib in colorectal cancer from a
phase Ib REGONIVO study is encouraging. The present study was conducted to evaluate …

Current immune checkpoint inhibiters (ICIs) have contrasting clinical results in poorly
immunogenic cancers such as microsatellite-stable colorectal cancer (MSS-CRC) …

Background The tumor microenvironment (TME) plays a crucial role in tumorigenesis,
progression, and therapeutic response in many cancers. This study aimed to …

Colorectal cancer (CRC) is one of the most common diseases in the world. Tumor
immunotherapy is an innovative cancer treatment that acts by activating the human body's …

Simple Summary Despite the great achievements of cancer immunotherapy in a variety of
tumors, tumor heterogeneity and drug resistance still plague patients and clinical …

Colorectal cancer (CRC) is the third most prevalent cancer in the world. The PD-1/PD-L1
pathway plays a crucial role in modulating immune response to cancer, and PD-L1 …